Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrizio Stocchi

Showing results (61-70 of 253) with videos related to

Pageof 26
Sort By:
Current Medical Research and Opinion|September 5, 2008
Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover studyFabrizio Stocchi, Bonnie P Hersh, Burton L Scott, et al.
Parkinson'S Disease|July 15, 2015
L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised StudyFabrizio Stocchi, Laura Vacca, Paola Grassini, et al.
Clinical Neuropharmacology|June 5, 2003
Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's diseaseFabrizio Stocchi, Alfredo Berardelli, Laura Vacca, et al.
Clinical Neuropharmacology|November 11, 2006
End-of-dose wearing off in Parkinson disease: a 9-question survey assessmentMark Stacy, Robert Hauser, Wolfgang Oertel, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 29, 2018
Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicineMargherita Fabbri, Joaquim J Ferreira, Andrew Lees, et al.
Future Microbiology|October 21, 2020
The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot studyFederica Del Chierico, Paola Grassini, Andrea Quagliariello, et al.
Expert Review of Neurotherapeutics|June 6, 2017
Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPAAndrew J Lees, Joaquim Ferreira, Olivier Rascol, et al.
Clinical Neuropharmacology|July 21, 2006
Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatmentGiovanni Palleschi, Antonio Luigi Pastore, Fabrizio Stocchi, et al.
Expert Review of Neurotherapeutics|February 2, 2023
Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approachAndrew Lees, Eduardo Tolosa, Fabrizio Stocchi, et al.
Parkinsonism & Related Disorders|November 11, 2021
Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's diseaseC Warren Olanow, Fabrizio Stocchi, Elizabeth L Peckham, et al.
Pageof 26

Showing results (61-70 of 253) with videos related to

Sort By:
Pageof 26
Current Medical Research and Opinion|September 5, 2008
Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover studyFabrizio Stocchi, Bonnie P Hersh, Burton L Scott, et al.
Parkinson'S Disease|July 15, 2015
L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised StudyFabrizio Stocchi, Laura Vacca, Paola Grassini, et al.
Clinical Neuropharmacology|June 5, 2003
Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's diseaseFabrizio Stocchi, Alfredo Berardelli, Laura Vacca, et al.
Clinical Neuropharmacology|November 11, 2006
End-of-dose wearing off in Parkinson disease: a 9-question survey assessmentMark Stacy, Robert Hauser, Wolfgang Oertel, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 29, 2018
Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicineMargherita Fabbri, Joaquim J Ferreira, Andrew Lees, et al.
Future Microbiology|October 21, 2020
The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot studyFederica Del Chierico, Paola Grassini, Andrea Quagliariello, et al.
Expert Review of Neurotherapeutics|June 6, 2017
Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPAAndrew J Lees, Joaquim Ferreira, Olivier Rascol, et al.
Clinical Neuropharmacology|July 21, 2006
Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatmentGiovanni Palleschi, Antonio Luigi Pastore, Fabrizio Stocchi, et al.
Expert Review of Neurotherapeutics|February 2, 2023
Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approachAndrew Lees, Eduardo Tolosa, Fabrizio Stocchi, et al.
Parkinsonism & Related Disorders|November 11, 2021
Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's diseaseC Warren Olanow, Fabrizio Stocchi, Elizabeth L Peckham, et al.
Pageof 26